12:00 AM
Mar 29, 1999
 |  BC Week In Review  |  Clinical News  |  Regulatory

Glaxo Wellcome regulatory update

Glaxo said the U.K.'s Medicines Control Agency rejected its application to reintroduce Romozin troglitazone to treat Type II diabetes in the U.K. The...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >